+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Preterm Birth and PROM Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851356
  • Report
  • December 2018
  • Region: Global
  • 165 pages
  • Transparency Market Research
1 of 2

Global Preterm Birth and PROM Testing Market: Overview

This report analyzes the current and future scenario of the global preterm birth and PROM testing market. Increase in preterm births, rise in demand for point-of-care testing devices, surge in demand for cost-effective diagnostic tests are projected to drive the global preterm birth and PROM testing market during forecast period. Additionally, effective and early diagnosis and reduction in false positive tests are the factors driving demand for point-of-care testing devices for detection of preterm births.

The global preterm birth and PROM testing market report comprises an elaborate executive summary, which includes information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on test type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global preterm birth and PROM testing market.

Global Preterm Birth and PROM Testing Market: Key Segments

Based on test type, the global preterm birth and PROM testing market has been bifurcated into preterm birth tests and PROM tests. The preterm birth tests segment has been classified into pelvic exam, ultrasound, uterine monitoring, and biomarkers. The PROM tests segment has been categorized into nitrazine test, ferning test, pooling, ultrasound, fetal fibronectin test, biomarker, and others. The most commonly used method for the determination of preterm birth is through the use of biomarkers. PROM tests such as ultrasound, biomarkers, and fetal fibronectin tests are widely conducted in hospitals and clinics to determine the occurrence of PROM. In terms of end-user, the market has been categorized into hospital, diagnostics laboratories, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Preterm Birth and PROM testing Market: Regional Outlook

In terms of region, the global preterm birth and PROM testing market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global preterm birth and PROM testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. These players include QIAGEN, Hologic, Inc., Medix Biochemica, Biosynex, Abbott Laboratories, Clinical Innovations, LLC, Sera Prognostics, Inc., The Cooper Companies, Inc., NX Prenatal, Inc., and IQ Products.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Preterm Birth and PROM Testing Market

4. Market Overview
4.1. Global Preterm Birth and PROM Testing Market Outlook
4.2. Global Preterm Birth and PROM Testing Market Analysis and Forecasts, 2016-2026
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities

5. Key Insights
5.1. Technological Advancements
5.2. Expansion and Collaborations
5.2. Epidemiology of Preterm Birth, by Country

6. Global Preterm Birth and PROM Testing Market Analysis and Forecasts, by Test Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Test Type, 2016-2026
6.3.1. Preterm Birth Tests
6.3.1.1. Pelvic Exam
6.3.1.2. Ultrasound
6.3.1.3. Uterine Monitoring
6.3.1.4. Biomarkers
6.3.2. PROM Tests
6.3.2.1. Nitrazine Test
6.3.2.2. Ferning Test
6.3.2.3. Pooling
6.3.2.4. Ultrasound
6.3.2.5. Fetal Fibronectin Test
6.3.2.6. Biomarker Tests
6.3.2.5. Others
6.4. Market Attractiveness, by Test Type

7. Global Preterm Birth and PROM Testing Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2016-2026
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Others
7.4. Market Attractiveness, by End-user

8. Global Preterm Birth and PROM Testing Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region

9. North America Preterm Birth and PROM Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Test Type, 2016-2026
9.2.1. Preterm Birth Tests
9.2.1.1. Pelvic Exam
9.2.1.2. Ultrasound
9.2.1.3. Uterine Monitoring
9.2.1.4. Biomarkers
9.2.2. PROM Tests
9.2.2.1. Nitrazine Test
9.2.2.2. Ferning Test
9.2.2.3. Pooling
9.2.2.4. Ultrasound
9.2.2.5. Fetal Fibronectin Test
9.3.2.6. Biomarker Tests
9.3.2.5. Others
9.3. Market Value Forecast, by End-user, 2016-2026
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Others
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Test Type
9.5.2. By End-user
9.5.3. By Country

10. Europe Preterm Birth and PROM Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2016-2026
10.2.1. Preterm Birth Tests
10.2.1.1. Pelvic Exam
10.2.1.2. Ultrasound
10.2.1.3. Uterine Monitoring
10.2.1.4. Biomarkers
10.2.2. PROM Tests
10.2.2.1. Nitrazine Test
10.2.2.2. Ferning Test
10.2.2.3. Pooling
10.2.2.4. Ultrasound
10.2.2.5. Fetal Fibronectin Test
10.3.2.6. Biomarker Tests
10.3.2.5. Others
10.3. Market Value Forecast, by End-user, 2016-2026
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Test Type
10.5.2. By End-user
10.5.3. By Country/Sub-region

11. Asia Pacific Preterm Birth and PROM Testing Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Test Type, 2016-2026
11.2.1. Preterm Birth Tests
11.2.1.1. Pelvic Exam
11.2.1.2. Ultrasound
11.2.1.3. Uterine Monitoring
11.2.1.4. Biomarkers
11.2.2. PROM Tests
11.2.2.1. Nitrazine Test
11.2.2.2. Ferning Test
11.2.2.3. Pooling
11.2.2.4. Ultrasound
11.2.2.5. Fetal Fibronectin Test
11.3.2.6. Biomarker Tests
11.3.2.5. Others
11.3.Market Value Forecast, by End-user, 2016-2026
11.3.1. Hospitals
11.3.2. Diagnostic Laboratories
11.3.3. Others
11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Test Type
11.5.2. By End-user
11.5.3. By Country/Sub-region

12. Latin America Preterm Birth and PROM Testing Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Test Type, 2016-2026
12.2.1. Preterm Birth Tests
12.2.1.1. Pelvic Exam
12.2.1.2. Ultrasound
12.2.1.3. Uterine Monitoring
12.2.1.4. Biomarkers
12.2.2. PROM Tests
12.2.2.1. Nitrazine Test
12.2.2.2. Ferning Test
12.2.2.3. Pooling
12.2.2.4. Ultrasound
12.2.2.5. Fetal Fibronectin Test
12.3.2.6. Biomarker Tests
12.3.2.5. Others
12.3.Market Value Forecast, by End-user, 2016-2026
12.3.1. Hospitals
12.3.2. Diagnostic Laboratories
12.3.3. Others
12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Test Type
12.5.2. By End-user
12.5.3. By Country/Sub-region

13. Middle East & Africa Preterm Birth and PROM Testing Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Test Type, 2016-2026
13.2.1. Preterm Birth Tests
13.2.1.1. Pelvic Exam
13.2.1.2. Ultrasound
13.2.1.3. Uterine Monitoring
13.2.1.4. Biomarkers
13.2.2. PROM Tests
13.2.2.1. Nitrazine Test
13.2.2.2. Ferning Test
13.2.2.3. Pooling
13.2.2.4. Ultrasound
13.2.2.5. Fetal Fibronectin Test
13.3.2.6. Biomarker Tests
13.3.2.5. Others
13.3.Market Value Forecast, by End-user, 2016-2026
13.3.1. Hospitals
13.3.2. Diagnostic Laboratories
13.3.3. Others
13.4.Market Value Forecast, by Country/Sub-region, 2016-2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Test Type
13.5.2. By End-user
13.5.3. By Country/Sub-region

14. Competitive Landscape
14.1. Global Preterm Birth and PROM Testing Market Analysis, by Top Company Ranking, 2017
14.2. Company Profiles
14.2.1. QIAGEN
14.2.2. Hologic, Inc.
14.2.3. Medix Biochemica
14.2.4. Biosynex
14.2.5. Abbott Laboratories
14.2.6. Clinical Innovations, LLC.
14.2.7. Sera Prognostics, Inc.
14.2.8. Cooper Companies, Inc.
14.2.9. NX Prenatal, Inc.
14.2.10. IQ Products
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll